Terns Pharmaceuticals Inc (TERN NASDAQ) stock market data APIs
$3.7641
0.08(2.1%)
as of June 30, 2025
Try our APIs with
free plan!
Terns Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Prev. Close
3.7641
Open
3.8467
High
3.9792
Low
3.7641
52 wk Range
1.865-11.4
Market Cap
335 M
Shares Outstanding
87 338 K
Revenue
1 000 K
EPS
-0.26
Beta
-0.194
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Terns Pharmaceuticals Inc data using free add-ons & libraries
Get Terns Pharmaceuticals Inc Fundamental Data
Terns Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 1 000 K
- EBITDA: -103 560 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-12
- EPS/Forecast: -0.2702
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Terns Pharmaceuticals Inc News
New
Terns pharmaceuticals CEO Burroughs buys $90k in shares
Amy L. Burroughs, Chief Executive Officer of Terns Pharmaceuticals , Inc. (NASDAQ:TERN), recently purchased 23,314 shares of the company’s common stock at a price of $3.8702 per share. The transact...
Terns completes enrollment in Phase 2 obesity drug trial
FOSTER CITY, Calif. - Terns Pharmaceuticals, Inc. (NASDAQ:TERN), a $321 million market cap biotech company currently trading below its InvestingPro Fair Value, has completed enrollment in its Phase 2 ...
Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions
Phase 1 clinical study of TERN-601 demonstrated differentiated profile in 28-day study; topline data were presented in September 2024 Phase 2 FALCON clinical trial of TERN-601 completed enrollment; 1...
Citizens JMP reiterates Terns Pharmaceuticals stock rating on positive data
Citizens JMP analyst Silvan Tuerkcan reiterated a Market Outperform rating and $20.00 price target on Terns Pharmaceuticals (NASDAQ:TERN), a $350 million market cap biotech company. According to Inv...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
